Ferran Guedea

Ferran Guedea

Auto-generated profile, based on publicly available information

Ferran Guedea

Radiation Oncology Department, Catalan Institute of Oncology, Avinguda de La Gran Via de L'Hospitalet, L'Hospitalet de Llobregat, 199-203, 08908, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in JMIR Research Protocols
Verified
Journal Article
Open access
VWValentin Walker
Valentin Walker
ACAnne Crijns
Anne Crijns
HLHans Langendijk
Hans Langendijk
DSDaan Spoor
Daan Spoor
RVRozemarijn Vliegenthart
Rozemarijn Vliegenthart
Sophie JacobSophie Jacob
Sophie Jacob
Breast cancer is the most common cancer among women, and radiotherapy plays a major role in its treatment. However, breast cancer radiotherapy can lead to incidental irradiation of the heart, resulting in an increased risk for a variety of heart diseases arising many years after radiotherapy. Therefore, identifying breast cancer patients at the highest risk for radiation-induced cardiac complications is crucial for developing strategies for primary and secondary prevention, which may contribute to healthy aging. There is still a need for precise knowledge on the relationship between radiation dose to specific cardiac structures and early subclinical cardiac changes and their occurrence over time that could finally lead to cardiac complications. The MEDIRAD EARLY HEART study aims to identify and validate new cardiac imaging and circulating biomarkers of radiation-induced cardiovascular changes arising within first 2 years of breast cancer radiotherapy and to develop risk models integrating these biomarkers combined with precise dose metrics of cardiac structures based on three-dimensional dosimetry. The EARLY HEART study is a multicenter, prospective cohort study in which 250 women treated for breast cancer and followed for 2 years after radiotherapy will be included. Women treated with radiotherapy without chemotherapy for a unilateral breast cancer and aged 40-75 years meet the inclusion criteria. Baseline and follow-up data include cardiac measurements based on two-dimensional speckle-tracking echocardiography, computed tomography coronary angiography, cardiac magnetic resonance imaging, and a wide panel of circulating biomarkers of cardiac injury. The absorbed dose will be evaluated globally for the heart and different substructures. Furthermore, the dose-response relationship will allow modeling the radiation-induced occurrence and evolution of subclinical cardiac lesions and biomarkers to develop prediction models. This study details the protocol of the MEDIRAD EARLY HEART study and presents the main limits and advantages of this international project. The inclusion of patients began in 2017. Preliminary results are expected to be published in 2019, and complete analysis should be published in 2021. The MEDIRAD EARLY HEART study will allow identifying the main cardiac imaging and blood-based determinants of radiation-induced cardiac injuries to better propose primary and secondary preventive measures in order to contribute to enhanced patient care and quality of life. ClinicalTrials.gov NCT03297346; https://clinicaltrials.gov/ct2/show/NCT03297346 (Archived by WebCite at http://www.webcitation.org/72KS7MIUU). RR1-10.2196/9906.

1 January 2010 in Brachytherapy
Verified
Journal Article
Closed access
FPFrancesca Pistis
Francesca Pistis
FGFerran Guedea
Ferran Guedea
JPJoan Pera
Joan Pera
CMCristina Gutiérrez Miguélez
Cristina Gutiérrez Miguélez
MVMontse Ventura
Montse Ventura
LLLuis Linares
Luis Linares

1 May 2007 in Cancer/Radiothérapie
Verified
Journal Article
Closed access
DPD. Peiffert
D. Peiffert
JMJ.-J. Mazeron
J.-J. Mazeron
FGF. Guedea
F. Guedea
RNR. Nisin
R. Nisin

1 January 2011 in Gaceta Sanitaria
Verified
Journal Article
Open access
VBVirginia Becerra Bachino
Virginia Becerra Bachino
FCFrancesc Cots
Francesc Cots
FGFerran Guedea
Ferran Guedea
JPJoan Pera
Joan Pera
ABAna Boladeras
Ana Boladeras
MFMontserrat Ferrer
Montserrat Ferrer
ResumenObjetivoComparar los costes de los tratamientos más establecidos para el cáncer de próstata localizado según grupos de riesgo, edad y comorbilidad, desde la perspectiva del proveedor asistencial.MétodosComparación de costes en pacientes reclutados consecutivamente entre 2003 y 2005 en una unidad funcional de tratamiento del cáncer de próstata. La utilización de servicios hasta 6 meses después del inicio del tratamiento se obtuvo de las bases de datos hospitalarias, y los costes directos se estimaron mediante cálculo microcoste. La información sobre las características clínicas de los pacientes y los tratamientos recogió prospectivamente. Los costes se compararon mediante tests no paramétricos de comparación de medianas (Kruskall-Wallis) y un modelo semilogarítmico de regresión múltiple.ResultadosLa diferencia de costes fue estadísticamente significativa: medianas de 3229.10 €, 5369.00 € y 6265.60 € para los pacientes tratados con radioterapia conformacional externa 3D, braquiterapia, y prostatectomía radical retropública, respectivamente (p<0,001). En el análisis multivariado (R2 ajustada=0,8), los costes medios de la braquiterapia y de la radioterapia externa fueron significativamente menores que los de la prostatectomía (coeficiente -0,212 y -0,729, respectivamente).ConclusionesLa prostatectomía radical resultó ser la opción terapéutica de mayor coste. En general, los costes estimados en nuestro estudio son inferiores a los publicados en otros ámbitos. La opción terapéutica explica gran parte de los costes, y tanto la comorbilidad como el grupo de riesgo no mostraron efecto independiente del tratamiento sobre los costes totales.AbstractObjectiveTo compare the initial costs of the three most established treatments for clinically localized prostate cancer according to risk, age and comorbidity groups, from the healthcare provider's perspective.MethodsWe carried out a cost comparison study in a sample of patients consecutively recruited between 2003 and 2005 from a functional unit for prostate cancer treatment in Catalonia (Spain). The use of services up to 6 months after the treatment start date was obtained from hospital databases and direct costs were estimated by micro-cost calculation. Information on the clinical characteristics of patients and treatments was collected prospectively. Costs were compared by using nonparametric tests comparing medians (Kruskall-Wallis) and a semi-logarithmic multiple regression model.ResultsAmong the 398 patients included, the cost difference among treatments was statistically significant: medians were €3,229.10, €5,369.00 and €6,265.60, respectively, for the groups of patients treated with external 3D conformal radiotherapy, brachytherapy and radical retropublic prostatectomy, (p<0.001). In the multivariate analysis (adjusted R2=0.8), the average costs of brachytherapy and external radiotherapy were significantly lower than that of prostatectomy (coefficient -0.212 and -0.729, respectively).ConclusionsRadical prostatectomy proved to be the most expensive treatment option. Overall, the estimated costs in our study were lower than those published elsewhere. Most of the costs were explained by the therapeutic option and neither comorbidity nor risk groups showed an effect on total costs independent of treatment

9 August 2023 in BMC Immunology
Verified
Journal Article
Open access
PDF file
ILIsabel Linares-Galiana
Isabel Linares-Galiana
MBMiguel Angel Angel Berenguer Berenguer
Miguel Angel Angel Berenguer Berenguer
RCRut Cañas
Rut Cañas
DNDina Najjari
Dina Najjari
CMCristina Gutiérrez Miguélez
Cristina Gutiérrez Miguélez
MPMonica Pujol
Monica Pujol
Background: New combinations based on standard therapeutic modalities and immunotherapy require understanding the immunomodulatory properties of traditional treatments. The objective was to evaluate the impact of brachytherapy (BT) on the immune system of cervical cancer and to identify the best modality, High-dose-rate brachytherapy (HDR-BT) vs. Pulsed-dose-rate (PDR-BT), to target it. Methods: Nineteen patients enrolled in a prospective study received chemoradiation (CRT) and subsequently HDR-BT or PDR-BT. Peripheral blood samples were obtained for immunophenotyping analysis by flow-cytometry before CRT, BT, and two and four weeks after BT. The Friedman one-way ANOVA, Conover post hoc test, and the Wilcoxon signed-rank test were used to compare changes in cell populations at different periods, perform multiple pairwise comparisons and assess differences between treatment groups (PDR and HDR). Results: Natural killer cells (NKs) were the best target for BT. Patients receiving HDR-BT achieved significantly higher values ​​and longer time of the CD56dimCD16 + NK cells with greater cytotoxic capacity than the PDR-BT group, which presented their highest elevation of CD56-CD16 + NK cells. Furthermore, both BT modalities were associated with an increase in myeloid-derived suppressor cells (MDSCs), related to a worse clinical prognosis. However, there was a decrease in the percentage of CD4 + CD25 + Foxp3 + CD45RA + regulatory T cells (Tregs) in patients receiving HDR-BT, although there were no significant differences between BT. Conclusions: Immune biomarkers are important predictive determinants in cervical cancer. Higher cytotoxic NK cells and a trend toward lower values of Tregs might support the use of HDR-BT to the detriment of PDR-BT and help develop effective combinations with immunotherapy.

3 August 2021 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
HPHéctor Pérez-Montero
Héctor Pérez-Montero
OGO. Godino
O. Godino
ALA. Lozano
A. Lozano
LAL. Asiáin
L. Asiáin
IMI. Martínez
I. Martínez
ANArturo Navarro
Arturo Navarro